2016 tables: Institutions - life sciences - corporate

The 2016 tables are based on Nature Index data from 1 January 2015 to 31 December 2015.

Table criteria

# Institution Share 2015 Count 2015
1 F. Hoffmann-La Roche AG, Switzerland 37.91 86
2 Novartis International AG, Switzerland 37.45 110
3 GlaxoSmithKline plc. (GSK), United Kingdom (UK) 17.77 60
4 AstraZeneca plc, United Kingdom (UK) 14.40 43
5 BGI, China 12.97 52
6 Amgen Inc., United States of America (USA) 11.50 41
7 Pfizer Inc., United States of America (USA) 10.68 40
8 Merck & Co., Inc., United States of America (USA) 10.24 30
9 Eli Lilly and Company, United States of America (USA) 7.53 20
10 Sanofi, France 6.43 24
11 Bristol-Myers Squibb (BMS), United States of America (USA) 6.31 20
12 Johnson & Johnson, United States of America (USA) 6.05 23
13 New England Biolabs, Inc. (NEB), United States of America (USA) 5.18 10
14 Formosa Plastics Group, Taiwan 5.09 24
15 Ionis Pharmaceuticals, Inc., United States of America (USA) 4.78 19
16 Regeneron Pharmaceuticals, Inc., United States of America (USA) 4.43 11
17 Leidos Holdings, Inc., United States of America (USA) 3.97 53
18 Illumina, Inc., United States of America (USA) 3.87 24
19 Samsung Group, South Korea 3.29 22
20 Nippon Telegraph and Telephone Corporation (NTT), Japan 2.83 3
21 Sangamo Therapeutics Inc., United States of America (USA) 2.59 4
22 UCB S.A., Belgium 2.51 11
23 Takeda Pharmaceutical Company Limited, Japan 2.44 7
24 D. E. Shaw Research, United States of America (USA) 2.42 5
25 Osaka Bioscience Institute, Japan 2.41 6
26 Novo Nordisk A/S, Denmark 2.23 9
27 Gilead Sciences, Inc., United States of America (USA) 2.19 5
28 Daiichi Sankyo Co., Ltd., Japan 2.05 9
29 Thermo Fisher Scientific Inc., United States of America (USA) 2.00 17
30 AbbVie Inc., United States of America (USA) 1.83 4
31 23andMe, Inc., United States of America (USA) 1.78 10
32 Novimmune SA, Switzerland 1.71 2
33 Promega Corporation, United States of America (USA) 1.64 5
34 Techint Group, Italy 1.58 13
35 Pacific Biosciences of California, Inc., United States of America (USA) 1.44 6
36 Metabolon Inc., United States of America (USA) 1.43 6
37 Kirin Holdings Company Limited, Japan 1.43 2
38 E. I. du Pont de Nemours and Company (DuPont), United States of America (USA) 1.42 10
39 Natera, Inc., United States of America (USA) 1.42 2
40 Cell Signaling Technology, Inc., United States of America (USA) 1.39 11
41 Agilent Technologies, Inc., United States of America (USA) 1.37 8
42 Biogen Inc., United States of America (USA) 1.36 14
43 Alnylam Pharmaceuticals, Inc., United States of America (USA) 1.35 4
44 C. H. Boehringer Sohn AG & Co. KG (Boehringer Ingelheim), Germany 1.34 8
45 NOXXON Pharma AG, Germany 1.33 3
46 Adaptive Biotechnologies LLC, United States of America (USA) 1.29 5
47 Novozymes A/S, Denmark 1.25 5
48 The New Zealand Institute for Plant and Food Research Ltd., New Zealand 1.25 13
49 MacroGenics, Inc., United States of America (USA) 1.24 2
50 Principia Biopharma, Inc., United States of America (USA) 1.24 2

Footnote

Each year, the Nature Index publishes tables based on counts of high-quality research outputs in the previous calendar year. Users please note:

  1. The data behind the tables are based on a relatively small proportion of total research papers, they cover the natural sciences only and outputs are non-normalized (that is, they don’t reflect the size of the country or institution, or its overall research output).
  2. The Nature Index is one indicator of institutional research performance. The metrics of Count and Share used to order Nature Index listings are based on an institution’s or country’s publication output in 82 natural-science journals, selected on reputation by an independent panel of leading scientists in their fields.
  3. Nature Index recognizes that many other factors must be taken into account when considering research quality and institutional performance; Nature Index metrics alone should not be used to assess institutions or individuals.
  4. Nature Index data and methods are transparent and available under a creative commons licence at natureindex.com.

The Nature Index database undergoes regular updating, corrections, adjustment of institutional hierarchies, and removal of retracted papers and thus the live website can differ from the frozen annual tables.